Nicox Ophthalmics, Inc.
Clinical trials sponsored by Nicox Ophthalmics, Inc., explained in plain language.
-
New eye drop shows promise in lowering glaucoma pressure
Disease control CompletedThis study tested a new eye drop, NCX 470, against a standard treatment (latanoprost) in 696 people with open-angle glaucoma or high eye pressure. Participants used the drops once daily for up to 12 months. The main goal was to see how well NCX 470 lowers eye pressure compared to…
Phase: PHASE3 • Sponsor: Nicox Ophthalmics, Inc. • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
Eye drop study reveals how NCX 470 lowers pressure in glaucoma
Knowledge-focused CompletedThis study looked at how NCX 470 eye drops affect fluid movement inside the eye. 18 healthy volunteers or people with high eye pressure received the drops or a placebo for 8 days. Researchers measured fluid flow and drainage to understand how the drops work.
Phase: PHASE2, PHASE3 • Sponsor: Nicox Ophthalmics, Inc. • Aim: Knowledge-focused
Last updated May 11, 2026 20:37 UTC